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To the Editor
We thank Metcalfe et al, Alffenaar et al, Soman et al, and Raoult for their interest in our 
study [1]. Metcalfe et al raise 2 issues about the analysis and reporting of results [2]. 
Alffenaar and colleagues raise issues related to drug dosing [3]. Soman and colleagues raise 
concern about standardized treatment regimens [4]. Raoult refers to the potential utility of 
existing drugs that are not standard antituberculosis drugs [5]. We respond to each of these 
letters in turn.
Metcalfe and colleagues suggest that patients who remain culture negative after 1 month of 
treatment could not have acquired drug resistance and therefore might have been included in 
the denominator when calculating the proportion of patients with acquired drug resistance 
[2]. However, the reality and the math are more complicated for at least 3 reasons. First, we 
disagree that the target population “is presented as all patients with MDR [multidrug-
resistant] tuberculosis starting treatment with [second-line drugs].” The target population for 
this analysis was patients with at least one positive follow-up cultures as displayed in our 
Figure 1 [1]. Second, we described the excluded subset of patients as having no positive 
follow-up cultures rather than as having all negative follow-up cultures because these are not 
the same: 20.8% of the excluded group of patients did not complete treatment (ie, were 
classified as defaulting) after a median of <12 months (interquartile range, 5–16 months). 
Because “default” is a World Health Organization (WHO)–defined standard outcome 
category [6], it was the endpoint in our follow-up of these patients, and we cannot know 
whether these patients had any subsequent positive cultures. However, the duration of 
treatment for this group of patients is inadequate. These patients would be at high risk for 
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again becoming culture positive and for acquired drug resistance. Third, many of these 
patients already had baseline resistance to fluoroquinolones, second-line injectable drugs, or 
both. It would not be appropriate to include them in the denominator when calculating the 
frequency of acquired resistance to these same drugs. The exact percentages are uncertain 
because we did not receive baseline cultures for all these patients and did not recover viable 
mycobacteria from all cultures received. However, of the 340 viable baseline isolates we 
received among patients with no positive follow-up cultures, 6.8% had fluoroquinolone 
resistance, 8.5% had resistance to 1 or more second-line injectable drugs, 11.8% had 
resistance to either, and 3.5% had resistance to both.
Metcalfe and colleagues also discuss our use of propensity scores to control for potential 
confounding factors. Unlike large randomized controlled trials, in observational studies 
there is always the possibility of unmeasured confounders. This does not preclude the use of 
multivariable regression and propensity score methods in analyzing data from observational 
studies. To the extent possible, we addressed this concern by measuring as accurately and 
completely as possible not only factors known to be associated with the main predictor and 
outcome variables, but also a broad range of factors that might possibly be associated with 
the main predictor and outcome variables. We also implemented a careful, systematic, step-
by-step analytic strategy including sensitivity analyses to explore the robustness of the 
findings. Our data did not violate the so-called positivity assumption (ie, there were no 
known confounders in which everyone was either exposed or unexposed). Human 
immunodeficiency virus (HIV) infection was perhaps the most prominent risk factor 
affecting one country in particular in the “unexposed” (non–Green Light Committee [GLC]) 
group, but 10% of HIV-infected patients were in GLC-approved countries, and one-third of 
patients were not tested for HIV infection (distributed across all countries). When we 
stratified countries by HIV prevalence, HIV infection was not associated with acquired drug 
resistance. Nearly half of HIV-positive patients were receiving highly active antiretroviral 
treatment and therefore would be expected to have outcomes more similar to HIV-negative 
patients. Last, we carried out sensitivity analyses to test whether the results were dominated 
by the higher prevalence of HIV infection in South Africa, for example, by excluding 
patients with HIV (from all countries) from the analysis, and the results were very close to 
the results we reported. For the association between GLC status and acquired XDR 
(extensively drug-resistant) tuberculosis, the adjusted odds ratios with and without HIV-
infected patients in the regression model were 0.21 (95% confidence interval [CI], .07–.63; 
P = .004) and 0.26 (95% CI, .09–.77; P = .01), respectively. For the association between 
GLC status and acquired fluoroquinolone resistance, the adjusted odds ratios were 0.23 
(95% CI, .09–.59; P = .001) and 0.28 (95% CI, .11–.71; P = .007), respectively.
We thank Alffenaar and colleagues for raising important issues related to the 
interrelationship between emergence of drug resistance and drug dosing based on 
pharmacokinetic and pharmacodynamic considerations [3]. There remains a great deal to be 
learned about optimal drug dosing, and we are aware of 2 clinical trials currently under way 
to assess the effect of different doses of antituberculosis drugs (ClinicalTrials.gov 
NCT01918397 and NCT01408914). Therapeutic drug monitoring may benefit many 
patients. In our cohort, the detailed treatment data are complex because drugs and doses 
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change repeatedly over the course of treatment based on drug susceptibility testing (DST) 
results, drug toxicity, clinical response to treatment, and drug availability. We are currently 
analyzing the impact of drug dosing on acquired drug resistance.
Soman and colleagues call attention to the risk of acquired drug resistance associated with 
standardized treatment regimens [4]. Our data add to the evidence that preexisting resistance 
to other drugs in the treatment regimen is one of the strongest risk factors for further 
acquired drug resistance [1]. Because resistance to second-line drugs is widespread among 
patients with MDR tuberculosis [6], we support WHO’s recommendations on DST for 
fluoroquinolones and second-line injectable drugs among patients with or suspected of 
having MDR tuberculosis [7, 8].
We agree with Raoult that many existing drugs with activity against M. tuberculosis have 
not been adequately studied, including some of the drugs classified by WHO as group 5 
drugs [7]. We recently launched a study to better characterize the effect of such drugs on 
MDR M. tuberculosis isolates from the Preserving Effective Tuberculosis Treatment Study, 
including most of the drugs named by Raoult. New and more effective drugs will help 
efforts to control highly drug-resistant forms of tuberculosis. We did not intend to imply that 
“only new drugs can be effective on XDR tuberculosis” as Raoult suggests. Bedaquiline and 
delamanid have been provisionally approved in the past 2 years for the treatment of MDR 
tuberculosis, and we urge clinicians and programs to use these drugs in a manner that does 
not lead to acquired resistance to these same drugs, that is, by ensuring there are at least 3 
other effective drugs in the treatment regimen.
Finally, we would like to thank again the authors of these 4 letters for raising important 
issues related to the treatment of MDR tuberculosis and the potential for further acquired 
resistance during treatment.
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